151 results about "Paclitaxel" patented technology

Many drugs useful in treating cancer are metabolized by CYP2C8 enzymes, by CYP3A4 enzymes, or both. The effects of concomitant administration of relacorilant and paclitaxel, a drug used to treat cancer that is a substrate for both CYP2C8 and CYP3A4, are disclosed herein.Relacorilant potently inhibited CYP2C8 and CYP3A4 in in vitro tests, indicating that co-administration of relacorilant and paclitaxel would increase paclitaxel plasma exposure more than 5-fold in vivo, requiring significant reductions in paclitaxel doses when co-administering paclitaxel with relacorilant.Surprisingly, paclitaxel plasma exposure increased only by about 80% instead of the expected more than 5-fold increase expected with concomitant relacorilant and paclitaxel administration. Applicant discloses safe methods of co-administering relacorilant and paclitaxel by reducing the dose of paclitaxel to about half the paclitaxel dose used when paclitaxel is administered alone. Relacorilant and such reduced doses of paclitaxel may be co-administered to treat cancer, e.g., ovarian or pancreatic cancer.

The invention belongs to the technical field of medicines, and discloses preparation and application of a paclitaxel-loaded liposome nano targeting preparation. The paclitaxel-entrapped nano-particles are prepared by adopting a film dispersion method, and micromolecular hyaluronic acid is entrapped on the surfaces of the lipid nano-particles by utilizing the charge effect. The bionic nano-drug provided by the invention is helpful for solving the problems of poor solubility, low bioavailability, high toxicity and the like of the anticancer drug paclitaxel. The hyaluronic acid has affinity with a glycoprotein CD44 receptor on the surface of a tumor cell, so that the nanoparticles are targeted and concentrated at a tumor part, the anti-tumor effect is improved, and the systemic toxicity of paclitaxel is reduced. The preparation process is simple, the cost is low, the stability is good, the repeatability is high, and the preparation method also has a better development prospect in the aspect of clinical application transformation.

The invention relates to the technical field of medical instruments, in particular to a paclitaxel drug coating balloon dilatation catheter and a preparation method and application thereof.The paclitaxel drug coating comprises a substrate layer, a middle layer and an outer layer; the substrate layer comprises paclitaxel and a hydrophilic excipient; the middle layer comprises a lipophilic excipient and a temperature response type polymer; and the outer layer comprises a pH sensitive polymer. The substrate layer is combined with the surface of the balloon, so that excellent conveying stability is provided, the medicine is effectively prevented from falling off prematurely in the conveying process of the catheter, and the firmness of the coating is improved; a micropore network structure is formed in the middle layer, the network structure is expanded under the body temperature condition, the porosity is increased, slow release of the medicine is achieved, the absorption amount of the medicine on the blood vessel wall is effectively increased, and the medicine effect time is prolonged; the solubility of the outer layer is improved in a slightly acidic blood vessel wall environment, so that the release of the medicine is further promoted, and the effective release of the medicine on the blood vessel wall is ensured.

The invention belongs to the technical field of pharmaceutical preparations. The invention discloses a multifunctional bionic nano preparation, a preparation method and application. According to the multifunctional bionic nano preparation, the ginsenoside Rg3 has the dual functions of a medicine and a membrane stabilizer, the platelet membrane has the natural targeting capability on circulating tumor cells and metastases, and meanwhile, the cationic liposome is used for adsorbing negatively-charged NETs nucleic acid protein compounds, so that potential reversal and active targeting are achieved, and the multifunctional bionic nano preparation has a good application prospect. And by co-carrying paclitaxel (PTX) and a photothermal agent (PCP) and integrating photothermal-chemotherapy-immunogenic death (ICD) induction functions, the tumor-related fibroblast activation can be effectively inhibited, circulating tumor cells can be efficiently captured, a tumor immune microenvironment can be remodeled, the tumor cells can be effectively killed, and tumor distal metastasis can be inhibited.

The application discloses a drug-loaded micelle capable of effectively crossing the blood-brain barrier, which is an amphiphilic conjugate composed of a reduction-sensitive paclitaxel prodrug and a nucleic acid complex, wherein the reduction-sensitive paclitaxel prodrug is used as a hydrophobic part, and the nucleic acid complex is used as a hydrophilic part, and the drug-loaded micelle is self-assembled in an aqueous environment; the reduction-sensitive paclitaxel prodrug is formed by the reaction of paclitaxel and a disulfide bond-containing linker; and the nucleic acid complex is formed by connecting an antisense oligonucleotide and an interfering RNA through a DNA bridge. The drug-loaded micelle exhibits superior blood-brain barrier penetration, effectively realizes enrichment in brain tumors, solves the problem of low blood-brain barrier penetration efficiency of existing nano-carriers, and provides an effective basis for brain drug delivery and brain diseases such as brain tumor imaging and treatment.

The application provides a combination drug of a PLA2G7 inhibitor and a chemotherapeutic drug and its use in resisting triple-negative breast cancer, and belongs to the technical field of medicines. The combination drug is a PLA2G7 inhibitor and a chemotherapeutic drug in the same or different specifications of unit preparations for simultaneous or separate administration, and a pharmaceutically acceptable carrier. The application first discovers and proves that the PLA2G7 inhibitor Darapladib can significantly enhance the anti-tumor activity of paclitaxel, 5-fluorouracil or cisplatin on triple-negative breast cancer, and meanwhile, the combination of the PLA2G7 inhibitor and paclitaxel has a synergistic effect in down-regulating the phosphorylation level of STAT3 protein in cancer cells and inhibiting the growth and proliferation of cancer cells; the combination of the PLA2G7 inhibitor and 5-fluorouracil also shows a synergistic effect in inhibiting the growth and proliferation of cancer cells. The application provides a new and effective combination drug strategy for improving the treatment effect of the chemotherapeutic drug on triple-negative breast cancer.

The invention relates to the technical field of biological medicines, in particular to application of dauricine in preparation of medicines for inhibiting ovarian cancer SKOV3 cell proliferation and treating ovarian cancer. The invention finds that dauricine has a remarkable inhibition effect on drug-resistant ovarian cancer cells, the dauricine has a clear dose-dependent relationship on the inhibition activity of the ovarian cancer cells SKOV3 in a concentration range of 1-50 mu M, and the IC50 value is 2 mu M. Meanwhile, the effect of inhibiting SKOV3 cell proliferation of the dauricine can be remarkably improved by combining the dauricine with paclitaxel or 5-fluorouracil. Therefore, dauricine can be used for preparing medicines for inhibiting ovarian cancer SKOV3 cell proliferation and improving ovarian cancer multidrug resistance, and has a good clinical application prospect.

The invention provides a preparation method of a polymer nanorod with a controllable and adjustable length-diameter ratio. The invention further provides a preparation method of the anti-tumor nano-drug, the anti-tumor nano-drug is prepared by the preparation method of the polymer nano-rod with the controllable and adjustable length-diameter ratio, and the paclitaxel nano-drug is prepared by the method. The three-step method adopted by the invention is based on a traditional emulsification method, special instruments and equipment are not needed, large-scale production is easy to realize, and the batch yield is relatively high; the preparation conditions are mild, and the drug activity can be effectively protected; the method is low in energy consumption, economical and efficient. According to the method, the length-diameter ratio of the nanorod can be controllably adjusted on the basis of not changing the raw material composition of the nanorod, the consistency of other parameters in the subsequent biological behavior research is favorably kept, the influence of mixed factors is reduced, and the reliability and repeatability of the research can be improved. Besides, when the length-diameter ratio of the nano-carrier is adjusted, only the process of heating fracture in the last step needs to be changed, so that the cost can be greatly saved, customized production is facilitated, or preclinical simple preparation is realized.

A taxane supramolecular nanocomposite. The supramolecular nanocomposite comprises a taxane active substance, including but not limited to paclitaxel, docetaxel, and cabazitaxel, as well as a self-assembling carrier, a high molecular polymer, and a dissolution promoter. The dissolution promoter may comprise one or more of alcohols, polybasic organic acids, and amino acids. Also disclosed are a preparation method and use of the supramolecular nanocomposite. The supramolecular nanocomposite is suitable for oral administration and topical application, providing effects such as increased local drug exposure concentration and efficacy, reduced systemic side effects, etc.

The invention discloses a nucleolin aptamer modified carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system as well as a preparation method and application thereof, and relates to the field of tumor treatment. The nucleolin aptamer AS1411 is coupled with glycolysis regulation nano-particles through covalent bonds, and the carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system comprises a carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system, a carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system and a carboxymethyl chitosan-based glycolysis regulation nano-drug delivery system, the glycolysis regulation nano-particles take carboxymethyl chitosan as a carrier skeleton, the carrier skeleton is loaded with a lonidamine derivative through grafting modification, and the nano drug delivery system can synchronously entrap paclitaxel. According to the invention, a synergistic treatment system integrating active targeting, metabolic regulation and chemotherapy is constructed, and by virtue of a multi-mechanism synergistic effect, an antitumor drug for inhibiting tumor cell activity, glycolysis or tumor metabolism reprogramming is prepared; the huge potentials of overcoming the drug resistance bottleneck of traditional chemotherapy, enhancing the curative effect and reducing the toxic and side effects are shown.

The present application belongs to the technical field of medicine, and particularly relates to albumin nanoparticles co-loading paclitaxel and BMS-202, a preparation method and application thereof. The present application comprises a carrier and a delivery carrier loaded with drugs; comprises a carrier and drugs loaded by a delivery carrier; the drugs are paclitaxel and an inhibitor BMS-202 co-loaded with paclitaxel, and the delivery carrier is human serum albumin. The present application comprises the following steps: step 1: paclitaxel and the inhibitor BMS-202 are dissolved in an organic solvent as an organic phase; step 2: human serum albumin is dissolved in water as an aqueous phase; step 3: the organic phase is directly added to the aqueous phase, and after mixing, ultrasonic treatment is immediately performed to make the system form a nanoparticle suspension; step 4: the nanoparticle suspension is subjected to purification treatment to remove the organic solvent and unencapsulated drugs, and albumin nanoparticles co-loading paclitaxel and BMS-202 are obtained. The present application is applied to the preparation of esophageal squamous cell carcinoma drugs. Compared with the prior art, the present application is relatively effective and safe in the treatment of esophageal cancer.

The present invention provides a use of paclitaxel cationic liposomes in the manufacture of a medicament for treating terminal solid cancer, a use of paclitaxel cationic liposomes and a systemic therapeutic agent in the manufacture of a medicament for treating terminal solid cancer, and a method for treating terminal solid cancer, in which a therapeutically effective amount of paclitaxel cationic liposomes is administered to a patient with terminal solid cancer, or a therapeutically effective amount of paclitaxel cationic liposomes and a systemic therapeutic agent is administered to a patient with terminal solid cancer.

The inventors have prepared a novel anti-Cath-D antibody (F1M1) that can reduce tumor growth in a Cath-D secreting basal-like TNBC cell line with strong immune infiltration, without significant toxicity. The F1M1 antibody prevents recruitment of immunosuppressive M2 polarized tumor-associated macrophages (TAMs) and induces activation of natural killer cells in the tumor, and the F1M1 also enhances activation of antitumor M1 polarized TAM, recruitment and maturation of conventional cDC1 dendritic cells in the tumor to promote antigen presentation and reduce depletion marker expression of CD4 + and CD8 + T cells in the tumor and drainage lymph nodes. It is worthy of noting that the affinity of the antibody F1M1 to Cath-D is better than that of the antibody F1 prepared by the inventor in advance. The inventors also have prepared a novel Fc-optimized F1M1-Fc + human antibody which can promote ADCC induction of cancer cells and CAF, improve anti-tumor efficacy, and trigger recruitment, activation and cytotoxic activity of NK cells in tumors. The F1M1-Fc + F1M1-Fc + can inhibit the growth of MDA-MB-231 and SUM159 TNBC cell xenografts and two TNBC-PDX (one of the TNBC-PDX is resistant to neoadjuvant chemotherapy), and has no obvious toxicity. In addition, the F1M1-Fc < + > improves the treatment effect of the paclitaxel and enzalutamide combined medicine. Thus, the present invention relates to anti-cathepsin-D antibodies and their use in the treatment of cancer, in particular triple negative breast cancer.

The application relates to the field of medical devices, in particular to a tracheal cannula end balloon, a preparation method thereof and a tracheal cannula. The tracheal cannula end balloon comprises a balloon body and a double-layer structure arranged on the surface of the balloon body, and the double-layer structure comprises a first nanofiber membrane and a second nanofiber membrane; the first nanofiber membrane comprises a first matrix material and paclitaxel, and the first matrix material comprises polyethylene glycol and polycaprolactone; the second nanofiber membrane comprises a second matrix material and ropivacaine, and the second matrix material comprises polyethylene glycol and polyvinylpyrrolidone. In the application, the double-layer structure design realizes layered release of the drugs, the outer-layer drugs rapidly relieve pain and inflammation, and the inner-layer drugs continuously inhibit cell proliferation, so that the problems caused by the tracheal cannula end balloon are comprehensively solved.

The invention discloses a composite elicitor for promoting taxus chinensis embryogenic stem cells to produce paclitaxel and application, and belongs to the technical field of biology. The compound elicitor consists of methyl jasmonate, indolebutyric acid and salicylic acid, and the working concentrations of the methyl jasmonate, the indolebutyric acid and the salicylic acid in a culture medium are respectively as follows: 50-800 mu mol / L of methyl jasmonate, 12.5-50 mu mol / L of indolebutyric acid and 0.1-0.5 mg / L of salicylic acid. Preferably, the jasmonic acid methyl ester is 200 [mu] mol / L, the indolebutyric acid is 25 [mu] mol / L, the salicylic acid is 0.5 mg / L, and 0.1-0.5 mg / L arachidonic acid can be selectively added. The composite elicitor is added in the early stage of the exponential growth phase of the taxus chinensis embryogenic stem cells, and the taxus chinensis embryogenic stem cells are continuously cultured for 5 days, so that the yield of paclitaxel reaches 27.52 mg / L and is 7.86 times that of blank control, and meanwhile, the maximum biomass is obtained. According to the invention, the synergistic interaction of the three elicitors is realized for the first time, the production period is remarkably shortened, a set of efficient and stable paclitaxel production system is established, and an innovative solution is provided for large-scale production of paclitaxel.

The invention provides a paclitaxel precursor nano-drug as well as a preparation method and application thereof, and belongs to the technical field of medicinal chemistry. Comprising a paclitaxel dimer prodrug and 7-ethyl10-hydroxy-camptothecin loaded on the paclitaxel dimer prodrug. According to the invention, a paclitaxel dimer prodrug is used as a self-assembly monomer to construct a PTX-SN38 synergistic treatment nano system, and the system has the advantages of dispersibility in water, biocompatibility, tumor specific response, synergistic treatment and the like, and can effectively solve the limitation of paclitaxel and SN38 in anti-tumor treatment.

The present application belongs to the field of microbial technology, and particularly relates to Streptomyces louchei WA11-1-1 and application thereof. The Streptomyces louchei WA11-1-1 provided by the present application is isolated from Periplaneta americana, and the strain is currently preserved in the Guangdong Microbial Culture Collection Center with a preservation number of GDMCC NO.61629 and a preservation date of May 19, 2021. The Streptomyces louchei WA11-1-1 provided by the present application can convert 7-xylose-10-deacetyl paclitaxel into 10-deacetyl paclitaxel in fermentation, and under the conditions of a xylan concentration of 0.8%, a fermentation time of 4d, a fermentation temperature of 28℃ and a liquid loading of 250mL, the conversion rate can reach 40.72±1.08%, which is 1.85 times higher than that before optimization, and the Streptomyces louchei WA11-1-1 can be used for preparation of anticancer drugs and has a wide application prospect.

Provided herein are uses of paclitaxel conjugated compounds and pharmaceutical compositions thereof in the treatment or prevention of proliferative, dermatological or ophthalmic diseases or disorders, such as cancer.

The invention belongs to the technical field of biological medicines, and particularly relates to application of saikoside D in preparation of medicines for inhibiting colorectal cancer Caco-2 cell proliferation and treating colorectal cancer. The invention finds that saikoside D has a remarkable inhibition effect on colorectal cancer cells, and in a concentration range of 1-50 [mu] M, the saikoside D has a definite dose-dependent relationship on the inhibition activity on the proliferation of colorectal cancer Caco-2 cells, and the inhibition activity is higher than that of paclitaxel and 5-fluorouracil. Meanwhile, the combination of saikoside D and paclitaxel can significantly improve the Caco-2 cell proliferation inhibition effect, which may be related to P-gp protein expression inhibition. Therefore, saikosaponin D can be used for preparing the medicine for inhibiting the proliferation of colorectal cancer Caco-2 cells and improving the drug resistance of paclitaxel to colorectal cancer, and has a good clinical application prospect.

Disclosed are a modified nucleic acid aptamer-paclitaxel conjugate, a preparation method therefor, and use thereof. The modified nucleic acid aptamer-paclitaxel conjugate comprises paclitaxel, a succinic acid linker, and an AS1411 aptamer modified with a G4 ligand. In the modified nucleic acid aptamer-paclitaxel conjugate, a nucleic acid aptamer and paclitaxel are coupled by means of a linking bond, and then a target conjugate is obtained by modifying the structure of the nucleic acid aptamer with a G-quadruplex stabilizer using a chemical method. The conjugate has better tumor targeting properties and ultimately specifically targets tumor cell surface proteins, thereby exhibiting anti-cancer activity for the treatment of cancer.

A depilatory emulsion containing paclitaxel is made from the following raw materials: 10% to 20% of oil, 8% to 12% of humectant, 4% to 6% of auxiliary emulsifier, 4% to 6% of emulsifier, 8% to 12% of paclitaxel solution, 0.5% to 1.0% of preservative, 0.01% to 0.05% of mineral, 0.05% to 0.10% of fragrance essential oil, and water for balance. This depilatory emulsion is designed to allow the paclitaxel and other active depilatory components to be absorbed by hair follicles while preventing absorption into dermis, thereby achieving advantages of an effective depilation, safety, absence of odor, reduced risk of skin allergy, and suitability for continuous use. A preparation method of this depilatory emulsion employs stepwise cooling and gradual emulsification to ensure that all components are fully dispersed and uniformly distributed, forming a stable emulsion system, which has advantages of simple steps and good emulsion stability.

The invention discloses an endovascular interventional targeted drug delivery system for treating pulmonary artery stenosis, and belongs to the technical field of minimally invasive interventional therapy. Compared with the prior art, the intravascular targeted drug delivery system balloon dilatation catheter provided by the invention can be used for interventional therapy of chronic thrombotic pulmonary hypertension (CTEPH). The endovascular intervention targeted drug delivery system for treating pulmonary artery stenosis, provided by the invention, adapts to a pulmonary artery anatomical path, and ensures the pushing property and flexibility in a complex delivery process. Anti-proliferation (such as paclitaxel and derivatives thereof or rapamycin and derivatives thereof) and anticoagulant drugs (such as heparin and tirofiban hydrochloride) are loaded on the surface of the balloon, mechanical expansion and local targeted drug delivery are achieved, and restenosis and thrombosis are inhibited.

The invention belongs to the technical field of medicines, and discloses a paclitaxel and silver nanoparticle loaded lipidosome nano-targeting preparation as well as preparation and application of the paclitaxel and silver nanoparticle loaded lipidosome nano-targeting preparation. According to the invention, nano-particles coated with silver nano-particles are prepared by adopting a film dispersion method. The nano-drug provided by the invention is helpful for solving the problems of poor water solubility, low bioavailability, poor tumor targeting property, strong toxic and side effects and the like of an anti-cancer drug paclitaxel and low bacterial uptake efficiency of an antibacterial drug Ag Nps, and provides a hyaluronic acid coated CD44 receptor targeted paclitaxel and Ag Nps co-loaded liposome nano-targeting preparation, so that the anti-tumor effect is improved. The preparation process is simple, the cost is low, the stability is good, and the repeatability is high.

To provide a combination for gastric cancer therapy which brings about enhanced therapeutic effects and reduced side effects.SOLUTION: Gastric cancer patients treated daily with the combination of the minelide prodrug and paclitaxel experienced significant negative side effects and cancer progression. Combination therapy of paclitaxel with a minelide prodrug administered according to the new regimen resulted in significantly improved therapeutic outcomes. The new dosing regimen comprises a 28-day cycle in which the minelide prodrug is administered once daily on days 1-5, 8-12, and 15-19 of the cycle, and paclitaxel is administered once daily on days 1, 8, and 15 of the cycle. The new dosing regimen was shown to be effective for treating gastric cancer and well tolerated in human patients.SELECTED DRAWING: Figure 5A

The invention discloses a construction method of recombinant escherichia coli for efficiently synthesizing piceatannol, and belongs to the technical field of biology. According to the invention, escherichia coli engineering bacteria for synthesizing piceatannol from L-tyrosine are firstly constructed, a metabolic pathway for high-yield synthesis of piceatannol by taking glycerol as a carbon source is further constructed, and then a non-carboxyl malonyl-coenzyme A (NCM) pathway is introduced, so that production of piceatannol is enhanced on the premise that cell growth is not affected, and the yield of piceatannol is increased. Accumulation of intermediate metabolites can be further reduced by using a co-localization strategy of enzyme, the catalytic efficiency of the enzyme is improved, and the yield of piceatannol synthesized from glycerol by escherichia coli is further improved; the Escherichia coli engineering strain can synthesize piceatannol with higher yield from glycerol, the concentration of other byproducts is greatly reduced, and the Escherichia coli engineering strain has a very good application prospect.

The application discloses a kind of endoplasmic reticulum of tumor cell can be targeted N -(2-hydroxypropyl) methacrylamide (HPMA) polymer-drug conjugate. The chemotherapeutic drug carried by the HPMA polymer is at least one of doxorubicin, epirubicin, pirarubicin, cisplatin, oxaliplatin, camptothecin, paclitaxel, gemcitabine, methotrexate, vinblastine, mitoxantrone, irinotecan, and the linker for connecting the drug and the HPMA polymer is at least one of hydrazone bond, amide bond, ester bond, disulfide bond, and ketosulfenyl bond. The HPMA polymer-drug conjugate targets the drug to the endoplasmic reticulum through receptor-ligand interaction, can cause severe endoplasmic reticulum stress, thereby transporting a large amount of calnexin to the tumor cell membrane surface, greatly improving the immunogenicity of tumor cells, and promoting tumor immunotherapy.

HA-paclitaxel conjugate for use in the loco-regional treatment of the mesothelioma, i.e., the malignant pleural mesothelioma, pericardial mesothelioma and peritoneal mesothelioma, preferably malignant pleural mesothelioma, and relative pharmaceutical compositions are described.

The invention discloses a paclitaxel clathrate compound as well as a preparation method and application thereof. The paclitaxel clathrate compound is formed by clathration of a bovine serum albumin-gamma-cyclodextrin compound and paclitaxel. The preparation method of the paclitaxel inclusion compound comprises the following steps: (1) synthesizing gamma-bromo-amide cyclodextrin; (2) preparing a bovine serum albumin-gamma-cyclodextrin compound; and (3) preparing the BSA-CD-PTX inclusion compound. The invention also discloses application of the paclitaxel clathrate compound in preparation of medicines for treating tumors. According to the paclitaxel inclusion compound, through a dual inclusion synergistic mechanism of a BSA hydrophobic pocket and a gamma-CD cavity, the solubilization limitation of a single carrier is remarkably broken through, the water solubility of paclitaxel is improved to 35 mM, and the drug loading capacity is synchronously optimized to 28%; premature release of drugs can be effectively avoided, explosive release in tumor cells can be potentially achieved, and the tumor cell killing activity of the compound is superior to that of an existing preparation. The preparation method of the paclitaxel clathrate compound is simple to operate and convenient for large-scale industrial production.

The application provides a paclitaxel molecular umbrella delivery system prodrug, a preparation method and application thereof. The paclitaxel molecular umbrella delivery system prodrug comprises a molecular umbrella target head part composed of two surface amphiphilic molecules connected by spermidine, a paclitaxel drug part, and a connecting group connecting the molecular umbrella target head part and the paclitaxel drug part through a disulfide bond; wherein the surface amphiphilic molecule is selected from cholic acid, deoxycholic acid or a sodium sulfonate thereof. Compared with paclitaxel, the paclitaxel molecular umbrella delivery system prodrug has significantly improved water solubility, lower toxicity to normal cells than free paclitaxel, and significantly improved safety; and the paclitaxel molecular umbrella delivery system prodrug has the following characteristics in a physiological environment: releasing active drugs in the high GSH / ROS microenvironment of tumor cells; and maintaining a prodrug state in normal cells.

The invention discloses a preparation method and application of a traditional Chinese medicine active ingredient compound paclitaxel capsule for treating cancers such as lung cancer. The capsule is a traditional Chinese medicine component compound prepared from taxus chinensis (Chinese yew), astragalus membranaceus, asparagus cochinchinensis and liquorice according to a certain processing method and proportion. The capsule comprises the following components in parts by mass: 15-20 parts of taxus chinensis (Chinese yew), 9-12 parts of astragalus membranaceus, 6-12 parts of asparagus cochinchinensis and 3-9 parts of liquorice. The preparation method comprises the following steps: drying, crushing, soaking, extracting, preparing, performing multi-stage filtration, performing multi-stage separation, and mixing various medicinal material extracts into the compound capsule in batches according to a certain proportion. Through reasonable compatibility, the traditional Chinese medicine conforms to the compatibility treatment rule of monarch, minister, assistant and guide, and has the effects of reducing swelling, removing stasis, eliminating evil, strengthening the body resistance, dispersing blood stasis and eliminating tumors. Various experimental studies show that the compound paclitaxel capsule and the optimized traditional Chinese medicine active ingredients for treating the cancers such as the lung cancer have an obvious treatment effect on the cancers such as the lung cancer, are convenient to take and free of toxicity, and provide a feasible new medicine for efficiently treating the cancers such as the lung cancer.